OPTIMIZERx Corporation Q1 2014 Operating Results
16 Mai 2014 - 7:25PM
Marketwired
OPTIMIZERx Corporation Q1 2014 Operating Results
ROCHESTER, MI--(Marketwired - May 16, 2014) - OPTIMIZERx Corp.
(OTCQB: OPRX) announced that it finished the first quarter for 2014
with revenues of $1,317,347 which is a 97% increase over the same
first quarter period in 2013, and the organization generated
positive net cash of $226,727 from operational activities. The
company reported a net loss of $653,315 for the first quarter
primarily due to two key factors: 1) a one-time litigation
settlement and 2) non cash payment of stock to vendors, former
executive and employees.
Despite nearly doubling sales over 1Q 2013, the company felt
that revenues could have been even higher based on two important
factors: 1) a technical issue within one of its most productive
channel partners effected its ability to distribute the promotional
program until the issue was resolved and 2) one of the company's
largest pharmaceutical clients interrupted their program to analyze
the promotional impact and return on investment.
Both matters have come to positive conclusions as the channel
partner has restored and is expanding SampleMD's promotions and the
manufacturer confirmed through a third party analytics company an
extremely high return on investment and has restored its
promotional programs to their fullest capacity.
The company also introduced its new Chief Financial Officer, Mr.
Doug Baker, who brings with him over 23 years of public company
experience and joins OPTIMIZERx after serving 18 years as CFO for a
publicly traded technology company in the nanotechnology field.
Prior to that, Doug held CFO and divisional controller positions at
large privately held companies after serving nearly ten years as a
CPA with Plante & Moran.
The company also launched its VoucherDVM solution that is
engaging leading veterinary platform providers whom are interested
in partnering with OPTIMIZERx to deliver similar automated savings
to animal owners while allowing veterinarians to remain competitive
in their pharmacy business.
To support the company's continued growth, OPTIMIZERx completed
the development and migration of its SampleMD 2.0 on-demand, rule
based content delivery platform while also updating its
infrastructure resulting in unsurpassed response time, increased
performance, simplified integrations and continuous
availability.
"It has been an exciting and productive first quarter for
OPTIMIZERx," said David Harrell, Chairman and CEO of OPTIMIZERx
Corporation, "and we are pleased with our first quarter results as
the company, its employees and partners are resolved in our mission
of growing the organization, being profitable and providing maximum
return for our shareholders."
For more information, please go to http://www.optimizerxcorp.com
or contact us at 248-651-6568.
About OptimizeRx Corp OPTIMIZERx Corp. (OTCQB: OPRX) provides
unique consumer and physician platforms to help patients better
afford and comply with their medicines and healthcare products,
while offering pharmaceutical and healthcare companies effective
ways to expand patient awareness, access and adherence to their
medications. For more information, please go to
www.optimizerxcorp.com or www.samplemd.com.
'SAFE HARBOR' This press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended and such section 21E of the Securities Act
of 1934, amended. These forward-looking statements should not be
used to make an investment decision. The words 'estimate,'
'possible' and 'seeking' and similar expressions identify
forward-looking statements, which speak only as to the date the
statement was made. The company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
Contact: Gabrielle Sabatini Email Contact 248-651-6568
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024